MIST Study: Clinical Trial

Learn about Avalyn’s MIST Study and the upcoming phase 2b clinical data on its inhaled pirfenidone program (AP01), focusing on patients with progressive pulmonary fibrosis (PPF). 

Whether you are new to clinical trials or have previous experience, this presentation will provide valuable information about advancing treatment options for pulmonary fibrosis (PF). Join Drs. Craig Conoscenti and Allison Turcillo to discover how your involvement can contribute to advancing treatment options. 

Topics: 

1. Introduction to Avalyn Pharma and inhaled pirfenidone (AP01) 
2. Review of clinical data from prior AP01 studies
3. Overview of the upcoming phase 2b MIST study for patients with PPF, including who can participate and how to find a study site